K. Canfell

The University of Sydney, a Joint Venture with Cancer Council NSW Daffodil Centre
Professor Karen Canfell is the inaugural Director of the Daffodil Centre, a joint venture between the University of Sydney and Cancer Council NSW. She is an epidemiologist, modeller, and a translationally-focused population health researcher. She has led evaluations of new cancer screening approaches for government agencies in several countries. She currently leads Compass, which is the first major international experience of cervical screening in an HPV-vaccinated population. Her team’s work underpins the 2017 transition of the National Cervical Screening Program in Australia from Pap smears to 5-yearly HPV-based screening. She currently has active collaborative modelling grants from the US NIH and WHO to model cervical cancer prevention in the USA and globally. Her work as one of the co-leads of the WHO Cervical Cancer Elimination Modelling Consortium was presented and discussed at the Executive Board of the World Health Assembly in 2020 and supported the formal resolution by WHO to support the cervical cancer elimination initiative, launched in late 2020. Most recently she led modelling to support new WHO cervical screening guidelines, launched in July 2021.

Author Of 12 Presentations

LONGITUDINAL OUTCOMES FROM THE FIRST PHASE OF THE COMPASS TRIAL IN AUSTRALIA: RCT OF PRIMARY HPV VS CYTOLOGY SCREENING IN AN HPV-VACCINATED POPULATION (ID 956)

Presenter
Lecture Time
06:39 PM - 06:51 PM

BENEFITS, HARMS AND COST-EFFECTIVENESS OF CERVICAL SCREENING IN 78 LOW-INCOME AND LOWER-MIDDLE INCOME COUNTRIES: MODELLING TO SUPPORT WHO 2021 CERVICAL SCREENING GUIDELINES (ID 301)

Presenter
Lecture Time
06:13 PM - 06:25 PM

IMPACT OF DISRUPTIONS TO ESTABLISHED CERVICAL SCREENING PROGRAMS ACROSS A RANGE OF HIGH-INCOME COUNTRY PROGRAM DESIGNS: COVID-19 AS AN EXAMPLE (ID 177)

Presenter
Lecture Time
02:17 PM - 02:29 PM

BENEFITS AND HARMS OF CERVICAL SCREENING IN HIV POSITIVE WOMEN: AN ANALYSIS TO INFORM UPDATED CERVICAL CANCER SCREENING GUIDELINES FOR WOMEN LIVING WITH HIV (ID 311)

Presenter
Lecture Time
02:25 PM - 02:37 PM

NATIONAL EXPERIENCE IN THE FIRST TWO YEARS OF PRIMARY-HPV CERVICAL SCREENING IN AN HPV-VACCINATED POPULATION IN AUSTRALIA: OBSERVATIONAL STUDY (ID 180)

Presenter
Lecture Time
10:01 AM - 10:13 AM

BENEFITS AND HARMS OF PRIMARY HPV SCREENING APPROACHES TAILORED TO VACCINATION STATUS IN USA: A CISNET-CERVICAL COMPARATIVE MODELLING STUDY (ID 345)

Presenter
Lecture Time
06:05 AM - 06:10 AM

COST EFFECTIVENESS OF HPV SCREENING IN A TANZANIAN POPULATION VACCINATED AGAINST HPV (ID 297)

Presenter
Lecture Time
06:00 AM - 06:05 AM

Increased burden of HPV cancers: another collateral damage of the COVID-19 pandemic? (ID 1149)

Presenter
Lecture Time
10:55 AM - 11:08 AM

IMPACT OF COVID-19 ON CERVICAL CANCER ELIMINATION TARGETS IN 78-LMICS: MODELLED PREDICTIONS OF ADDITIONAL CASES AND DEATHS DUE TO 12-MONTH DELAYS IN SCALE-UP TARGETS (ID 307)

Presenter
Lecture Time
02:29 PM - 02:41 PM

ACHIEVING ELIMINATION IN AUSTRALIA’S INDIGENOUS WOMEN: HOW CAN WE CLOSE THE GAP? (ID 178)

Presenter
Lecture Time
06:45 AM - 06:50 AM

BENEFITS, HARMS AND COST-EFFECTIVENESS OF HPV-MRNA TESTING IN 78 LOW-INCOME AND LOWER-MIDDLE INCOME COUNTRIES: MODELLING TO SUPPORT WHO 2021 CERVICAL SCREENING GUIDELINES (ID 334)

Presenter
Lecture Time
12:22 PM - 12:34 PM

MODEL VALIDATION OF TEST SENSITIVITY OF VISUAL INSPECTION WITH ACETIC ACID (VIA) AGAINST LONGITUDINAL TRIALS IN INDIA (ID 296)

Presenter
Lecture Time
07:25 AM - 07:30 AM

Presenter of 2 Presentations

Increased burden of HPV cancers: another collateral damage of the COVID-19 pandemic? (ID 1149)

Presenter
Lecture Time
10:55 AM - 11:08 AM

LONGITUDINAL OUTCOMES FROM THE FIRST PHASE OF THE COMPASS TRIAL IN AUSTRALIA: RCT OF PRIMARY HPV VS CYTOLOGY SCREENING IN AN HPV-VACCINATED POPULATION (ID 956)

Presenter
Lecture Time
06:39 PM - 06:51 PM

Poster Author Of 5 e-Posters